EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) is a late-stage specialty pharmaceutical and drug delivery company focused on developing and commercializing therapeutics and drug delivery mechanisms for treating diseases of the eye. EyeGate’s technology addresses two of the most prevalent issues in ophthalmic care: the existing lack of patient adherence and patient safety. EyeGate is committed to advancing its delivery technology and therapeutic candidates with a goal of bringing new, potentially superior treatment options to patients who will most likely benefit. For more information, visit the company’s website at www.eyegatepharma.com